Single use Bioreactors Market – Trends Forecast Till 2030

Market Snapshot

Market Overview

The global Single use Bioreactors Market size was estimated at USD 5.2 billion in 2023 and is projected to reach USD 9.2 billion in 2030 at a CAGR of 17.8% during the forecast period 2024-2030.

The global market for single-use bioreactors (SUBs) has witnessed significant growth and transformation driven by the biopharmaceutical industry's increasing demand for efficient, flexible, and cost-effective bioprocessing solutions. Traditionally, stainless-steel bioreactors were prevalent in biologics manufacturing, but the shift towards SUBs has accelerated due to their numerous advantages.

SUBs, also known as disposable bioreactors, utilize single-use bioreactor bags instead of stainless-steel vessels. This eliminates the need for costly and time-consuming cleaning and sterilization procedures associated with traditional bioreactors. The adoption of SUBs is driven by their cost efficiency, with potential savings of up to 40% compared to stainless-steel systems. Moreover, SUBs offer shorter production timelines (~35%), reduced energy and water consumption (45%-50%), and enhanced product yield, making them highly attractive for biopharmaceutical companies aiming to streamline manufacturing processes and increase productivity.

The market growth is further propelled by the rapid expansion of the biopharmaceutical sector, particularly in the development and production of biologics such as monoclonal antibodies, vaccines, cell therapies, and gene therapies. These complex biomolecules require precise and sterile manufacturing environments, where SUBs excel in providing flexibility and minimizing contamination risks.

During the COVID-19 pandemic, SUBs played a critical role in the rapid scale-up and production of vaccines and treatments. Biopharmaceutical companies leveraged the flexibility and speed of SUBs to respond swiftly to the global health crisis, highlighting their pivotal role in emergency response scenarios and pandemic preparedness.

Technological advancements in SUBs continue to drive market growth, with manufacturers incorporating features such as advanced sensors, electronic process logs, remote monitoring capabilities, and enhanced safety measures. These innovations improve process control, efficiency, and scalability, meeting the evolving needs of biopharmaceutical manufacturing.

Geographically, North America has been a dominant market for SUBs, attributed to robust investment in biopharmaceutical R&D, favorable regulatory policies, and a strong presence of industry players. However, regions like Europe and Asia-Pacific are also witnessing rapid adoption of SUBs, supported by increasing biopharmaceutical investments and infrastructure development.

Looking ahead, the single-use bioreactors market is poised for continued expansion as biopharmaceutical companies seek agile and cost-effective solutions for bioprocessing. Regulatory support for SUBs is growing, with agencies like the FDA and EMA recognizing their benefits in ensuring product safety and quality. As innovation in bioprocessing technologies advances, SUBs are expected to play an increasingly integral role in shaping the future of biomanufacturing, driving efficiencies and accelerating the delivery of life-saving therapies to patients worldwide.

Delvens Industry Expert's Standpoint

The single-use bioreactors market is experiencing robust growth driven by the pharmaceutical and biotechnology sectors' increasing focus on supply chain resilience. These bioreactors have emerged as critical tools due to their pre-sterilized, ready-to-use nature, which simplifies inventory management and accelerates deployment compared to traditional stainless-steel bioreactors. They enable rapid switchovers between batches without the need for extensive cleaning and validation, enhancing production flexibility and responsiveness to fluctuating demand and supply chain disruptions.

Looking ahead, the market for single-use bioreactors is poised for expansion with continued advancements in bioprocessing technologies and increasing adoption across diverse applications. The demand is expected to rise with the exploration of new uses in gene therapy, tissue engineering, and stem cell culture. Additionally, the shift towards continuous bioprocessing, facilitated by single-use bioreactors, is anticipated to drive productivity gains in biomanufacturing. Manufacturers are also focusing on enhancing adaptability and flexibility of single-use bioreactor systems to meet customized process requirements, further bolstering market growth.

Moreover, the expansion of single-use bioreactors beyond biopharmaceuticals into biofuels, industrial enzymes, and other bio-based products underscores their versatility and market potential. With ongoing innovations and regulatory support, particularly in ensuring product safety and quality, single-use bioreactors are set to play an increasingly integral role in shaping the future of bioprocessing technologies worldwide.

Market Portfolio

Key Findings

• On the basis of product, In 2022, the single-use bioreactors market is categorized into segments including single-use bioreactor systems, single-use media bags, single-use filtration assemblies, and other products. Leading this market is the single-use bioreactor systems segment, driven by its cost-effective benefits such as reduced capital investment, lower operating costs, and a smaller environmental impact compared to traditional stainless-steel bioreactors. These advantages make single-use bioreactor systems a preferred choice among biopharmaceutical companies seeking efficient and sustainable bioprocessing solutions, thereby contributing significantly to the segment's dominant position in the market.

• On the basis of drug type, In 2022, the single-use bioreactors market is segmented by drug type into stirred-tank single-use bioreactors, wave-induced single-use bioreactors, bubble-column single-use bioreactors, and other types such as hybrid bioreactors and single-use bioreactors with vertically perforated discs. Leading this segmentation is the stirred-tank single-use bioreactors segment, driven by their widespread use in aerobic microbial cell culture bioproduction. Their popularity stems from their efficient mixing capabilities, which are crucial for supporting aerobic processes in biopharmaceutical manufacturing. As a result, stirred-tank single-use bioreactors maintain a significant market share, catering to the demand for scalable and flexible bioprocessing solutions in the pharmaceutical and biotechnology industries.

• On the basis of type of molecule, the single-use bioreactors market is categorized by molecule type into segments including monoclonal antibodies (mAbs), vaccines, gene-modified cells, stem cells, and other molecules. Leading this segmentation is the monoclonal antibodies (mAbs) segment, driven by rising demand for single-use bioreactors in mAbs manufacturing. This preference is influenced by their cost-effectiveness, quicker changeover processes, and reduced initial investment compared to traditional bioreactor systems. These factors underscore the dominance of monoclonal antibodies in driving the adoption of single-use bioreactors across the biopharmaceutical industry, supporting their significant market share in 2022.

• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America's held the largest Single use Bioreactors Market share the single-use bioreactors (SUBs) market stems from rising chronic illnesses and demand for new drug development.

Regional Analysis

North America to Dominate the Market

• North America dominates the single-use bioreactors (SUBs) market, fueled by increasing prevalence of chronic diseases and robust drug development initiatives. With over 34.2 million Americans affected by diabetes and significant mortality from heart disease annually, there is a heightened demand for new drug development. The region boasts a substantial infrastructure with numerous FDA-registered facilities dedicated to biologics and human drugs, providing ample opportunities for SUBs adoption. Moreover, ongoing innovations and product launches, such as Agilitech's bioreactor controller, underscore North America's leadership in advancing biopharmaceutical manufacturing capabilities, driving market growth and expansion across the region.

Competitive Landscape

• Applikon Biotechnology
• Biolinx Labsystems
• Celartia
• Cell Culture Company
• Cellexus
• Cercell
• CESCO Bioengineering
• Cytiva
• Eppendorf
• Merck Millipore
• Pall Corporation
• PBS Biotech
• PerfuseCell
• ProlifeCell
• Sartorius Stedim Biotech
• Solaris Biotech
• Synthecon
• Thermo Fisher Scientific

Recent Developments

• In November 2022, Sartorius GA (Germany) announced plans to expand operations through the establishment of new R&D laboratories and the digitalization and automation of equipment. These initiatives aim to meet increasing demand from the biopharmaceutical industry.

• In August 2022, Thermo Fisher Scientific (US) inaugurated its largest single-use technology manufacturing facility in Greater Nashville with a USD 105 million investment. This expansion aims to meet rising demand for bioprocessing materials crucial for producing vaccines and advanced therapies for diseases like cancer.

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
   
• Gain authentic and granular data access for the Single use Bioreactors Market to understand the trends and the factors involved in changing market situations.
   
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
   
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope